Active ingredient: Oxaliplatin - Brands, Medical Use, Clinical Data

Brands, Medical Use, Clinical Data

Drug Category

• Antineoplastic Agents

Dosage Forms

• Not Available

Brands / Synonyms

DACPLAT; Eloxatin; Oxalatoplatin; Oxalatoplatinum; Oxaliplatin [Usan:Inn:Ban]; Oxaliplatino [Spanish]; Oxaliplatinum [Latin]; Oxaloplatine [French]; Oxaloplatino [Spanish]

Indications

For the treatment of malignant neoplasm of colon, rectum, and ovary

Pharmacology

Oxaliplatin selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of Oxaliplatin-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed.

Mechanism of Action

after activationm it binds preferentially to the guanine and cytosine moieties of DNA, leading to cross-linking of DNA, thus inhibiting DNA synthesis and function.

Absorption

Not Available

Toxicity

Not Available

Biotrnasformation / Drug Metabolism

Not Available

Contraindications

ELOXATIN should not be administered to patients with a history of known allergy to ELOXATIN or other platinum compounds.

Drug Interactions

No specific cytochrome P450-based drug interaction studies have been conducted. No pharmacokinetic interaction between 85 mg/m² ELOXATIN and infusional 5-FU has been observed in patients treated every 2 weeks. Increases of 5-FU plasma concentrations by approximately 20% have been observed with doses of 130 mg/m² ELOXATIN dosed every 3 weeks. Since platinum containing species are eliminated primarily through the kidney, clearance of these products may be decreased by coadministration of potentially nephrotoxic compounds; although, this has not been specifically studied.